| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2022 | 162.53% | EF Hutton | → $11 | Initiates Coverage On | → Buy |
| 03/11/2022 | 759.19% | HC Wainwright & Co. | $34 → $36 | Maintains | Buy |
| 11/02/2021 | 711.46% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/07/2021 | 663.72% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 07/28/2020 | 472.79% | Colliers Securities | → $24 | Initiates Coverage On | → Buy |
Lantern Pharma Questions & Answers
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on November 1, 2022. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 162.53% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on November 1, 2022 so you should expect the next rating to be made available sometime around November 1, 2023.
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a initiated with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $4.19, which is within the analyst's predicted range.
